中西药联用治疗慢性乙型肝炎的疗效分析

The Combined effects of Matrine, Ara-AMP and Thymic peptide in treatment of CHB

探讨国产抗病毒药物单磷酸阿糖腺苷(Ara-AMP)、苦参素、胸腺肽联合治疗慢性乙型肝炎(CHB)的疗效。方法将136例CHB患者分为4组:A组30例,单独使用Ara-AMF,400mg加入10％葡萄糖200ml静滴,1/d,30d为1个疗程;B组30例,单独使用苦参素注射液6ml肌注,1/d,3个月为1个疗程;C组46例,苦参素、胸腺肽、Ara-AMF联合应用,胸腺肽100mg,静滴,1/d,30d为1个疗程;D组30例,为对照组,仅应用保肝药。结果 A、B、C组均有不同程度抗病毒作用,治疗后1年HBeAg、HBVDNA转阴率分别为33.33％、33.33％、52.34％和33.33％、30％、50％,均明显高于对照组(10％和10％),P<0.05;C组ALT复常率高于A、B2组。P<0.05。HBeAg、HBV DNA转阴率与A、B组比较无明显差异,P>0.05。结论 Ara-AMP、苦参素、胸腺肽联合治疗CHB疗效可靠,无毒副作用。

Objective To study the effects of anti-virus agents Marine, Adenine arabinoside Adenosine monophosphate (Ara-Amp) and Thymic peptide in treatment of chronic hepati- tis B(CHB). Methods A total of 136 CHB patients were di- vided into 4 groups: Group A (n = 30) treated with Ara-Amp only, 400mg/d, vein drip for 30d. Group B (n = 30) treated with marine only, 6ml/d muscle injection for 90d. Group C (n=46) treated with Marine, Ara-Amp and Thymic peptide (60mg/d), for 30d. Group D (control group, n = 30) treated with liver protection medicine only. Results Anti-virus effects to different extents were found in groups A, B and C. After one-year treatment, the ratio of HBeAg (33.33%, 33.33%, 52.34%) and HBV DNA (33.33%, 30%, 50%) turning to negative in groups A, B, C, was higher than that in control group (10%, 10%, P<0.05). The ratio of ALT turning to normal (84.78%) in group C was higher than that in group A or B (P<0.05). The ratio of HBeAg, HBV DNA turning to negative in group C was not different from that in group A or 17, (P >0.05). Conclusions CHB therapy with Marine, Ara- Amp and Thymic peptide has reliable effect but no side effect.